关于新里程健康科技集团股份有限公司 前期会计差错更正事项说明的鉴证报告 第1页 关于新里程健康科技集团股份有限公司 前期会计差错更正事项说明的鉴证报告 毕马威华振专字第2503293号 新里程健康科技集团股份有限公司董事会： 我们接受委托，对后附的新里程健康科技集团股份有限公司（以下简称"新里程股份公 司"）前期会计差错更正事项说明（以下简称"更正说明"）执行了有限保证的鉴证业务。 一、董事会对更正说明的责任 按照《企业会计准则第28号——会计政策、会计估计变更和差错更正》、中国证券监督 管理委员会《公开发行证券的公司信息披露编报规则第19号——财务信息的更正及相关披露》 的相关规定编制更正说明是新里程股份公司董事会的责任，这种责任包括设计、执行和维护与 更正说明编制相关的内部控制，以及保证更正说明内容的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 第2页 关于新里程健康科技集团股份有限公司 前期会计差错更正事项说明的鉴证报告 毕马威华振专字第2503293号 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对更正说明发表鉴证结论。我们按照《中国注册 会计师其他鉴证业务准则第 3101 ...

新里程健康科技集团股份有限公司 自 2024 年 1 月 1 日 至 2024 年 12 月 31 日止年度财务报表 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 审计报告 毕马威华振审字第 2514768 号 新里程健康科技集团股份有限公司全体股东： 一、审计意见 我们审计了后附的新里程健康科技集团股份有限公司 (以下简称"新里程股份") 财务报 表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、 合并及母公司现金流量表、合并及 ...

报告期内，我作为新里程健康科技集团股份有限公司（以下简称"公司"） 的独立董事在任职期间严格遵守《公司法》、《上市公司治理准则》、《上市公司独 立董事管理办法》、《深圳证券交易所股票上市规则》（以下简称《股票上市规则》）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 （以下简称《主板上市公司规范运作》）以及《公司章程》等法律法规、规范性 文件的规定，忠实、勤勉地履行职责，切实维护公司整体利益和全体股东特别是 中小股东的合法权益。现将 2024 年度的履职情况报告如下： 一、独立董事的基本情况 （一）个人基本情况 2024 年度独立董事述职报告 新里程健康科技集团股份有限公司 2024 年度独立董事述职报告 （浦军） 各位股东及股东代表： 浦军：男，1976 年出生，中国国籍，无境外永久居留权，博士。曾任对外 经济贸易大学国际商学院讲师、新里程健康科技集团股份有限公司独立董事；现 任对外经济贸易大学国际商学院会计学教授，中国全聚德（集团）股份有限公司 独立董事，中国科技出版传媒股份有限公司独立董事，科沃斯机器人股份有限公 司独立董事。 （二）是否存在影响独立性的情况说明 本人未在公 ...

2024 年度独立董事述职报告 新里程健康科技集团股份有限公司 2024 年度独立董事述职报告 （杜晨光） 各位股东及股东代表： 1 2024 年度独立董事述职报告 报告期内，我作为新里程健康科技集团股份有限公司（以下简称"公司"） 的独立董事在任职期间严格遵守《公司法》、《上市公司治理准则》、《上市公司独 立董事管理办法》、《深圳证券交易所股票上市规则》（以下简称《股票上市规则》）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 （以下简称《主板上市公司规范运作》）以及《公司章程》等法律法规、规范性 文件的规定，忠实、勤勉地履行职责，切实维护公司整体利益和全体股东特别是 中小股东的合法权益。现将 2024 年度的履职情况报告如下： 一、独立董事的基本情况 （一）个人基本情况 杜晨光：男，1981 年出生，中国国籍，无境外永久居留权，博士。曾任北 京国科文明之光科技有限公司副总经理；现任北京国科九合科技有限公司董事长， 中国科学院大学校友会科技转化校友联合会秘书长，新里程健康科技集团股份有 限公司独立董事。 （二）是否存在影响独立性的情况说明 本人未在公司担任除独立董事以外的任何职 ...

各位股东及股东代表： 2024 年度独立董事述职报告 新里程健康科技集团股份有限公司 2024 年度独立董事述职报告 （王敬民） 报告期内，我作为新里程健康科技集团股份有限公司（以下简称"公司"） 的独立董事在任职期间严格遵守《公司法》、《上市公司治理准则》、《上市公司独 立董事管理办法》、《深圳证券交易所股票上市规则》（以下简称《股票上市规则》）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 （以下简称《主板上市公司规范运作》）以及《公司章程》等法律法规、规范性 文件的规定，忠实、勤勉地履行职责，切实维护公司整体利益和全体股东特别是 中小股东的合法权益。现将 2024 年度的履职情况报告如下： 一、独立董事的基本情况 （一）个人基本情况 王敬民：男，1973 年出生，中国国籍，无境外永久居留权，本科。曾任北 京常春藤医学高端人才联盟副主席，中国老龄产业协会-医养结合与健康管理专 业委员会秘书长，北京市老龄产业协会健康医养专业委员会秘书长；现任北京常 春藤医学高端人才联盟秘书长，新里程健康科技集团股份有限公司独立董事。 （二）是否存在影响独立性的情况说明 本人未在公司担任除独立董 ...

新里程健康科技集团股份有限公司 2024 年度独立董事述职报告 （王蓓） 2024 年度独立董事述职报告 各位股东及股东代表： 报告期内，我作为新里程健康科技集团股份有限公司（以下简称"公司"） 的独立董事在任职期间严格遵守《公司法》、《上市公司治理准则》、《上市公司独 立董事管理办法》、《深圳证券交易所股票上市规则》（以下简称《股票上市规则》）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 （以下简称《主板上市公司规范运作》）以及《公司章程》等法律法规、规范性 文件的规定，忠实、勤勉地履行职责，切实维护公司整体利益和全体股东特别是 中小股东的合法权益。现将 2024 年度的履职情况报告如下： 一、独立董事的基本情况 事会第十六次会议至第六届董事会第三十二次会议，2024 年第一次临时股东大 会至 2024 年第六次临时股东大会、及 2023 年年度股东大会。由于本人于 2024 年 7 月 15 日被选举为公司独立董事，本人出席董事会、股东大会情况如下： （一）个人基本情况 王蓓：女，1980年10月出生，中国国籍，澳大利亚永久居留权，澳大利亚特 许注册会计师（ACPA），博士 ...

根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等要求， 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）董事会就 公司在任独立董事王蓓女士、杜晨光先生、王敬民先生、池轶婷女士的独立性情 况进行评估并出具如下专项意见： 经核查独立董事王蓓女士、杜晨光先生、王敬民先生、池轶婷女士的任职经 历以及签署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东单位担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情 况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关要求。 新里程健康科技集团股份有限公司 新里程健康科技集团股份有限公司 新里程健康科技集团股份有限公司 董事会对独立董事独立性评估的专项意见 董 事 会 2025年4月28日 - 1 - ...

2024 年度独立董事述职报告 新里程健康科技集团股份有限公司 2024 年度独立董事述职报告 （池轶婷） 各位股东及股东代表： 报告期内，我作为新里程健康科技集团股份有限公司（以下简称"公司"） 的独立董事在任职期间严格遵守《公司法》、《上市公司治理准则》、《上市公司独 立董事管理办法》、《深圳证券交易所股票上市规则》（以下简称《股票上市规则》）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 （以下简称《主板上市公司规范运作》）以及《公司章程》等法律法规、规范性 文件的规定，忠实、勤勉地履行职责，切实维护公司整体利益和全体股东特别是 中小股东的合法权益。现将 2024 年度的履职情况报告如下： 一、独立董事的基本情况 （一）个人基本情况 池轶婷：女，1980 年出生，澳大利亚籍，硕士。曾任北京鼎汇赢网络信息 技术有限公司运营总监，北京安慧邻里教育咨询有限公司运营总监，北京时代融 聚教育咨询有限公司运营总监；现于德恒国际有限公司任职，新里程健康科技集 团股份有限公司独立董事。 2024 年度，公司共召开 16 次董事会会议及 7 次股东大会，分别为第六届董 事会第十六次会议至第六 ...

Financial Performance - The company's operating revenue for 2024 was CNY 3,799,010,310, representing a decrease of 2.95% compared to CNY 3,914,292,010 in 2023[18]. - Net profit attributable to shareholders of the listed company reached CNY 114,765,521, a significant increase of 296.13% from CNY 28,971,936 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 97,080,260, marking a 223.48% increase from CNY 30,011,373 in 2023[18]. - The net cash flow from operating activities was CNY 438,505,853, up 36.64% from CNY 320,925,112 in the previous year[18]. - Basic earnings per share increased to CNY 0.0349, a rise of 292.13% compared to CNY 0.0089 in 2023[18]. - The company reported a net profit of 58,049,108.86 in Q4 2024, recovering from a loss of -6,517,066.26 in Q3 2024[23]. - The total revenue for Q1 2024 was 953,406,293.16, while Q2 2024 saw an increase to 1,047,335,973.86[23]. - Non-recurring gains totaled 17,685,261.00 in 2024, a significant recovery from -1,039,437.68 in 2023[25]. Strategic Developments - The company has transitioned from a single pharmaceutical manufacturing business to a dual-driven model of "medical + pharmaceutical" in the health industry[17]. - The company emphasizes the development of a comprehensive hospital and multiple specialized branches as part of its regional medical model[17]. - The company aims to enhance its operational quality and profitability through strategic restructuring, scale expansion, and talent development, leading to increased market share and effective revenue[45]. - The company is expanding its hospital network with new projects, including a 600-bed oncology specialty building at Xuyi County Hospital starting construction in October 2023 and an 800-bed new area at Chongzhou Second Hospital expected to be operational by 2025[44]. - The company plans to establish specialized treatment centers for high-demand areas such as oncology and cardiovascular diseases, increasing the revenue share from these specialties[91]. Market and Industry Insights - The healthcare industry is projected to grow significantly due to an aging population, with the elderly population expected to reach 4.2 billion by 2035[28]. - The total number of medical institutions in China reached 1,034,901 by the end of 2023, with a net increase of 1,983 institutions[30]. - National health expenditure exceeded 9.12 trillion yuan, maintaining a GDP share of 7.1%[31]. - The average annual medical expenses per capita increased to 6,480 yuan, reflecting rising healthcare costs[31]. - The disparity in medical resources is evident, with top-tier hospitals in eastern coastal regions having 2.3 times more beds than those in western regions[34]. Governance and Compliance - The company emphasizes the importance of protecting the rights of minority shareholders during shareholder meetings[101]. - The company is committed to improving investor relations through various channels, including interactive platforms and investor briefings[95]. - The company has established a value management system and disclosed a valuation enhancement plan[99]. - The company is focused on business collaboration and resource injection from controlling shareholders to promote growth[95]. - The company has implemented a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders[104]. Human Resources and Employee Management - The total number of employees at the end of the reporting period is 9,097, with 9,333 employees receiving salaries[142]. - The company has 6,924 technical personnel, representing a significant portion of the workforce[143]. - The company has implemented a performance evaluation mechanism to ensure fair salary distribution based on annual operational plans[144]. - Over the past years, the company has organized more than 20 training sessions covering various topics, including strategic management and professional skills enhancement[145]. - The company is committed to building a dual career development path to enhance organizational capabilities and support business expansion[145]. Risk Management - The company has detailed potential risks in its report, urging investors to maintain awareness of investment risks[3]. - The internal control system has been effectively implemented, ensuring compliance with laws and regulations[159]. - The company has established a comprehensive risk assessment system to identify and analyze risks related to achieving internal control objectives[159]. - The company actively protects shareholder and creditor rights, ensuring transparency and compliance with disclosure obligations[167]. Investment and Financial Strategy - The company confirmed a non-public offering of shares with a subscription amount of RMB 210,000,000[181]. - The company will manage raised funds in a dedicated account as per regulations, ensuring they are not used for non-designated purposes[182]. - The company is seeking credit facilities from East Asia Bank (China) and China Merchants Bank as part of its financial strategy[135]. - The company has committed to ensuring that the non-public offering application documents do not contain any false records or misleading statements[181]. Environmental and Social Responsibility - The company has invested in environmental protection measures, ensuring compliance with relevant regulations and maintaining stable operation of all environmental facilities[169]. - The company has not reported any significant environmental issues or administrative penalties during the reporting period[166]. - The company emphasizes employee rights and has implemented comprehensive human resource policies to support employee welfare and development[167].

Financial Performance - The company's revenue for Q1 2025 was ¥796,152,158.94, representing a decrease of 16.49% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥25,651,871.15, down 9.35% year-on-year[5]. - Basic and diluted earnings per share were both ¥0.0076, reflecting an 8.43% decrease from the previous year[5]. - Total operating revenue decreased to ¥796,152,158.94 from ¥953,406,293.16, representing a decline of approximately 16.5% year-over-year[18]. - Net profit for the period was ¥24,568,864.12, down from ¥30,278,299.46, reflecting a decrease of approximately 18.5% year-over-year[19]. - The net profit attributable to the parent company was ¥25,651,871.15, compared to ¥28,298,589.87, a decline of about 9.2% year-over-year[19]. Cash Flow - The net cash flow from operating activities was negative at -¥37,994,893.16, a decline of 295.69% compared to the previous year[5]. - The net cash flow from operating activities was -37,994,893.16, compared to 19,415,797.80 in the previous period, indicating a decline in operational cash generation[21]. - Total cash inflow from financing activities was 905,404,638.47, up from 525,764,043.63, reflecting increased borrowing and investment receipts[22]. - The net cash flow from financing activities was 265,867,299.41, a significant improvement from -28,626,219.91 in the previous period, indicating better financing conditions[22]. - The net cash flow from investing activities was -281,232,018.53, compared to -85,999,556.27 previously, showing a significant increase in cash outflows for investments[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,697,480,188.77, an increase of 0.30% from the end of the previous year[5]. - The company's total assets amount to approximately 6.70 billion RMB, with a slight decrease from 6.68 billion RMB at the beginning of the period[15]. - Total liabilities amounted to ¥4,625,175,397.49, slightly down from ¥4,636,462,586.44, a decrease of approximately 0.2%[17]. - Total equity increased to ¥2,072,304,791.28 from ¥2,040,729,633.97, reflecting an increase of about 1.5%[17]. Research and Development - The company's R&D expenses increased by 30.52% to ¥4,398,653.82 due to higher external R&D spending[9]. - Research and development expenses rose to ¥4,398,653.82 from ¥3,370,011.31, an increase of approximately 30.4% year-over-year[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 66,333[12]. - The largest shareholder, Beijing New Mileage Health Industry Group Co., Ltd., holds 24.38% of shares, totaling 825,927,323 shares[12]. - The top ten shareholders include various investment funds and individuals, with significant holdings and some shares under pledge or freeze[12][13]. Operational Metrics - Cash received from sales of goods and services was ¥716,100,676.97, down from ¥890,867,731.57, indicating a decrease of about 19.6% year-over-year[20]. - Cash outflows for operating activities totaled 767,237,059.59, compared to 887,874,207.46 in the previous period, showing a reduction in operational expenses[21]. - Cash inflow from other operating activities was 13,141,489.46, compared to 16,422,273.69 previously, indicating a decline in miscellaneous operational cash receipts[21]. - The company reported a credit impairment loss of ¥4,123,361.88, compared to a loss of ¥9,800,623.67 in the previous period, indicating an improvement in credit quality[18].